Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “Tap early and often” versus hospitalization  John.

Slides:



Advertisements
Similar presentations
Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles  Ryan G. Steward,
Advertisements

Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome
Lynn B. Davis, M. D. , M. S. , Sara J. Champion, M. S. , Steve O
Andrew J. Krentz, M.D., Elizabeth Barrett-Connor, M.D. 
Male infertility: a biomarker of individual and familial cancer risk
Lynn B. Davis, M. D. , M. S. , Sara J. Champion, M. S. , Steve O
Outpatient versus Inpatient Observation after Percutaneous Native Kidney Biopsy: A Cost Minimization Study Am J Nephrol 2011;34:64–70 - DOI: /
Coordinating Care in Patients With Cirrhosis
Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D
Postparacentesis bilateral massive vulvar edema in a patient with severe ovarian hyperstimulation syndrome  Dimitrios Vavilis, M.D., Stergios Tzitzimikas,
Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study  Arianna D'Angelo, M.D., Rachel.
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.
Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial 
L. G. Maldonado, W. C. Busato, L. M. Rossi, T. C. Bonetti, A
Konstantinos Pantos, M. D. , Evangelos Makrakis, M. D
Management of the first in vitro fertilization cycle for unexplained infertility: a cost- effectiveness analysis of split in vitro fertilization-intracytoplasmic.
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
Predictive value of embryo grading for embryos with known outcomes
Insurance mandates and trends in infertility treatments
Predicted value of renin activity in a woman who had severe ovarian hyperstimulation syndrome with internal jugular vein thrombosis  Fung-Wei Chang, M.D.,
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Erratum Fertility and Sterility
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Prospective evaluation of luteal phase length and natural fertility
Oocyte cryopreservation
Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant?  H. Browne, A. Armstrong,
Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian.
Amir M. Khan, M. D. , Sunit Jariwala, M. D. , Harry Jay Lieman, M. D
A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone 
A new approach to ovarian reserve testing
Alternate indications for varicocele repair: non-obstructive azoospermia, pain, androgen deficiency and progressive testicular dysfunction  Peter N. Schlegel,
Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis  Laura P. Smith, M.D.,
Are intracytoplasmic sperm injection and high serum estradiol compounding risk factors for adverse obstetric outcomes in assisted reproductive technology? 
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
From partner's desk to iPad
Male infertility: a biomarker of individual and familial cancer risk
What are patients doing with their mosaic embryos
Clomiphene citrate at 50: the dawning of assisted reproduction
Mohamed Fawzy, M. D. , Mohamed Y. AbdelRahman, M. D. , Mohamed H
Cost-effectiveness analysis comparing continuation of assisted reproductive technology with conversion to intrauterine insemination in patients with low.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Keeping clinicians in research: the Clinical Research/Reproductive Scientist Training Program (CREST) strategy, 2006–2012  Rebecca S. Usadi, M.D., Ruben.
Lisa C. Grossman, B. A. , Konstantinos G. Michalakis, M. D
The role of fallopian tube anastomosis in training fellows: A survey of current reproductive endocrinology fellows and practitioners  Alicia Armstrong,
Image-guided drainage versus antibiotic-only treatment of pelvic abscesses: short-term and long-term outcomes  Justin To, M.D., Diana Aldape, M.D., Andrei.
A retrospective study on the use of dose-dependent letrozole to decrease cancer recurrence and adverse events in patients undergoing ovarian stimulation 
Simple tools for assessment of ovarian reserve (OR): individual ovarian dimensions are reliable predictors of OR  Stacea Bowen, M.D., John Norian, M.D.,
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Outcomes of spontaneous and assisted pregnancies in Turner syndrome: the U.S. National Institutes of Health experience  Tracy N. Hadnott, B.A., Harley.
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
A case of ovarian hyperstimulation syndrome associated with the methylenetetrahydrofolate reductase mutation gene  Filippo Ferrara, M.D., Francesco Meli,
Cabergoline and Ganirelix Therapy for Early Moderate to Severe Ovarian Hyperstimulation Syndrome (OHSS) Results in Faster Recovery than in Early Untreated.
A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T)  Marlene B. Goldman,
Fertility and Sterility: an evaluation
Cost and efficacy comparison of in vitro fertilization and tubal anastomosis for women after tubal ligation  Lauren B. Messinger, M.D., Connie E. Alford,
Sedigheh Borna, M.D., Azita Nasery, M.D.  Fertility and Sterility 
Impact of leuprolide acetate on luteal phase function in women undergoing controlled ovarian hyperstimulation and intrauterine insemination  Deirdre A.
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
The impact on ovarian reserve after laparoscopic ovarian cystectomy versus three-stage management in patients with endometriomas: a prospective randomized.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Experience with a patient-friendly, mandatory, single-blastocyst transfer policy: the power of one  John M. Csokmay, M.D., Micah J. Hill, D.O., Rebecca.
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
Diane De Neubourg, M. D. , Kathelijne Mangelschots, B. Sc
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
Treatment decision trends in the infertility patient journey from 78,958 cycles in a real- world database: impact of age, diagnosis, and year of treatment 
Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous?  John M. Norian, M.D., Eric D. Levens,
Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome  Kris Poppe, M.D., Ph.D., David Unuane,
Presentation transcript:

Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “Tap early and often” versus hospitalization  John M. Csokmay, M.D., Belinda J. Yauger, M.D., Melinda B. Henne, M.D., M.S., Alicia Y. Armstrong, M.D., M.H.S.C.R., John T. Queenan, M.D., James H. Segars, M.D.  Fertility and Sterility  Volume 93, Issue 1, Pages 167-173 (January 2010) DOI: 10.1016/j.fertnstert.2008.09.054 Copyright © 2010 Terms and Conditions

Figure 1 Cost-effective decision tree for management of OHSS. The initial arm is a decision node between inpatient or outpatient management. After deciding treatment route, all subsequent outcomes were based on probabilities extracted from literature or institutional retrospective chart review. The final outcome for either treatment arm was resolution of OHSS. Cost estimates from 2007 were used. Costs listed in each box of the outline are the total costs per patient enrolled for that treatment arm and outcome. Fertility and Sterility 2010 93, 167-173DOI: (10.1016/j.fertnstert.2008.09.054) Copyright © 2010 Terms and Conditions

Figure 2 (A) Cost variation through a range of inpatient hospital stay lengths. The cost of outpatient management arm is held constant in this one-way sensitivity analysis. Axes: x = length of inpatient hospitalization in days, y = total cost of treatment (U.S. dollars). The intersection of the lines demonstrates cost equivalence between two treatment arms, which occurs at less than 1 day of hospitalization. (B) Cost of primary outpatient management of OHSS through a range of probabilities of hospital admission. Inpatient management cost is held constant in this one-way sensitivity analysis. Axes: x = probability of hospital admission in primary outpatient treatment arm, y = total cost of treatment (U.S. dollars). The point of intersection between the two lines would represent cost equivalence, but, as shown, inpatient management remains more costly, even at high probabilities for hospitalization. Fertility and Sterility 2010 93, 167-173DOI: (10.1016/j.fertnstert.2008.09.054) Copyright © 2010 Terms and Conditions